Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine plus CBCM for ultra-high-risk prodromal psychosis
ACTRN12610000244000Phase 4Terminated
- Sponsor
- Orygen
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 4, randomised, double-blind trial in Psychosis Prodrome (APS) comparing Quetiapine + CBCM with Placebo + CBCM (2 arms). Primary endpoint: Transition to first-episode psychosis. Started May 2010; status: terminated.
02
Drugs
quetiapine
03
Conditions
Psychosis Prodrome (APS)
Beyond the preview
Go deeper on ACTRN12610000244000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000244000.